Spiro derivatives of the pyrazolo [1,5-d] [1,2,4] triazine ring system
and a process for the preparation thereof
    14.
    发明授权
    Spiro derivatives of the pyrazolo [1,5-d] [1,2,4] triazine ring system and a process for the preparation thereof 失效
    吡唑并[1,5-d] [1,2,4]三嗪环系的螺衍生物及其制备方法

    公开(公告)号:US4469692A

    公开(公告)日:1984-09-04

    申请号:US442451

    申请日:1982-11-17

    CPC分类号: C07D487/10

    摘要: A spiro derivative of the pyrazolo [1,5-d] [1,2,4] triazine ring system of the formula I ##STR1## wherein R.sub.1 and R.sub.2 represent, independently from each other, a hydrogen atom or a C.sub.1-4 alkyl group,R.sub.3 stands for a hydrogen atom, an unbranched or branched C.sub.1-4 alkyl, C.sub.2-5 alkenyl or benzyl group,R.sub.4 represents a hydrogen atom, an unbranched or branched C.sub.1-4 alkyl, C.sub.4-6 cycloalkyl, an unsubstituted or mono-halo or polyhalo benzyl group, andn is a whole number from 4 to 8,wherein R stands for an unbranched or branched C.sub.1-4 alkyl, or C.sub.4-6 cycloalkyl, C.sub.2-5 alkenyl, an unsubstituted or a monohalogeno or polyhalogenobenzyl group, and X represents a halogen or a 4-methyl-phenylsulfonyloxy group. Compounds of the formula I exhibit valuable CNS activities.

    摘要翻译: 式I的吡唑并[1,5-d] [1,2,4]三嗪环系的螺衍生物其中R 1和R 2彼此独立地表示氢原子或C 1-4 烷基,R3表示氢原子,无支链或支链C 1-4烷基,C 2-5烯基或苄基,R 4表示氢原子,无支链或支链C 1-4烷基,C 4-6环烷基,未取代或未取代的 单卤素或多卤代苄基,n为4至8的整数,其中R代表无支链或支链C 1-4烷基或C 4-6环烷基,C 2-5链烯基,未取代或单卤素或多卤代苄基 基团,X表示卤素或4-甲基 - 苯基磺酰氧基。 式I的化合物显示出有价值的CNS活性。

    Anorexigenic 4-[(3,4-dialkoxyphenyl)alkyl]-2-imidazolidinone derivatives
    19.
    发明授权
    Anorexigenic 4-[(3,4-dialkoxyphenyl)alkyl]-2-imidazolidinone derivatives 失效
    厌氧性4 - [(3,4-二烷氧基苯基)烷基] -2-咪唑烷酮衍生物

    公开(公告)号:US4308278A

    公开(公告)日:1981-12-29

    申请号:US90450

    申请日:1979-11-01

    摘要: 4-[(3,4-Dialkoxyphenyl)alkyl]-2-imidazolidinone derivatives having the formula I ##STR1## wherein R.sup.1 stands for a cycloalkyl group containing from 3 to 6 carbon atoms or benzyl group;R.sup.2 stands for hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms;R.sup.3 stands for hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms;R.sup.4 stands for hydrogen atom, or an alkyl group containing from 1 to 4 carbon atoms or an alkoxycarbonyl group containing from 1 to 4 carbon atoms; andR.sup.5 stands for hydrogen atom or an alkoxycarbonyl group containing from 1 to 4 carbon atoms,are prepared by(a) reducing a hydantoin derivative having the general formula II, wherein R.sup.1 and R.sup.2 are as defined above, with lithium aluminum hydride in a neutral organic solvent, or(b) hydrogenating catalytically an 1,3-dihydro-2H-imidazol-2-one derivative having the general formula III, wherein R.sup.1 and R.sup.3 are as defined above, while the meaning of R.sup.4 is hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms, or(c) reacting a carbamate derivative having the general formula IV, wherein R.sup.1 is as defined above, while R.sup.6 stands for an alkyl group containing from 1 to 4 carbon atoms, with an organic or inorganic base.The compounds having the formula I possess valuable therapeutical properties, mainly anorexigenic activity.

    摘要翻译: 4 - [(3,4-二烷氧基苯基)烷基] -2-咪唑啉酮衍生物,其具有式I其中R1代表含有3至6个碳原子的环烷基或苄基; R2代表氢原子或含有1至4个碳原子的烷基; R3代表氢原子或含有1至4个碳原子的烷基; R4表示氢原子或含有1至4个碳原子的烷基或含有1至4个碳原子的烷氧基羰基; 并且R5代表氢原子或含有1至4个碳原子的烷氧基羰基,是通过以下步骤制备的:(a)将具有通式II的乙内酰脲衍生物(其中R 1和R 2如上定义)与中性的氢化铝锂 有机溶剂,或(b)催化氢化具有通式III的1,3-二氢-2H-咪唑-2-酮衍生物,其中R 1和R 3如上所定义,而R 4的含义是氢原子或烷基 含有1至4个碳原子的基团,或(c)使具有通式IV的氨基甲酸酯衍生物与其中R 1如上定义,而R6代表含有1至4个碳原子的烷基,与有机或无机 基础。 具有式I的化合物具有有价值的治疗性质,主要是厌食症活性。